SoVote

Decentralized Democracy

House Hansard - 304

44th Parl. 1st Sess.
April 29, 2024 11:00AM
Context: House Hansard - 304 - Apr/29/24
Mr. Majid Jowhari (Richmond Hill, Lib.)
Madam Speaker, I am honoured to speak before the House today to discuss an issue of paramount importance to the health and safety of Canadians, which is the safety and the availability of natural health products, also known as NHPs. In order to make the natural health products market safer for consumers and support Canadians in making informed choices, last year our government expanded Vanessa's Law to include NHPs. Doing this allows the government to act when serious health and safety risks are identified, such as the ability to require a recall if products are unsafe. Our number one priority is to keep Canadians healthy and safe. Bill C-368 would remove the government's ability to ensure the safety and the efficacy of these crucial health products. Passing this bill would mean that the government could mandate the recall of a tube of lipstick or a head of lettuce, but not a contaminated supplement. That is why the government will be opposing this bill. I am aware that some members of the opposition may be supporting this bill. We look forward to it going to committee, if that is the case, to further cover the points I am about to cover. My remarks today will delve into the vital role that NHPs play in the lives of Canadians, the current landscape of NHPs and the need for greater oversight of NHPs to guarantee public safety. Before proceeding further, I must highlight the exceptional engagement from the community of Richmond Hill on this matter. Our office has received over 1,200 communications, including emails, petitions, phone calls and pamphlets from constituents who are deeply concerned about the regulation and the safety of NHPs. Since 2020, I have also met with the Canadian Health Food Association, which represents many NHP small business owners in my riding. One of those businesses is Platinum Naturals, whose team I met with this past February to hear their important feedback and their concern with respect to the impacts of the NHP regulations on their business. This overwhelming response from my constituents underscores a national discourse on the necessity of a regulatory framework that ensures the safety of NHPs and that supports small businesses operating in the industry, as well as respects the autonomy of Canadians in their health management practices. As I delve into the implications of Bill C-368, I want to first focus on the vital role NHPs play in the lives of Canadians, followed by the current landscape of NHPs and, lastly, the need for greater oversight to guarantee public safety. NHPs, which include vitamins, minerals, herbal remedies and daily-use products like toothpaste and sunscreen, are part of our integral health care practices. Their popularity is undeniable, with the number of authorized products in Canada skyrocketing from around 50,000 in 2004 to over 200,000 today. This demand underscores the critical importance of ensuring these products are not only effective, but also safe for Canadian families. It is fundamental to understand that although NHPs are lower risk, they are not without risk, especially if products are contaminated, advertised in a misleading manner or used improperly. As much as NHPs offer potential health benefits, the risks associated with substandard or improperly labelled NHPs underscore the need for appropriate oversight. I will now highlight the previous and the current legislative landscape of NHPs. In Canada, NHPs are regulated under the Food and Drug Act, and specifically under the natural health products regulations established in 2004. A pivotal moment in Canadian legislative history was the enactment of the Protecting Canadians from Unsafe Drugs Act, also known as Vanessa's Law, in 2014. This introduced improvements in Health Canada's ability to collect post-market safety information on drugs and medical devices and to take appropriate actions, such as issuing a mandatory recall when a serious risk to health care is identified. However, NHPs were not yet incorporated under the scope of this law. As a result, for close to a decade, Health Canada's ability to take action on NHPs when health and safety issues occur has been limited. This lack of equivalent safety power for NHPs has compelled Health Canada to depend on voluntary intervention by industry, which has not consistently worked in the past, to protect Canadians against real health and safety risks. A significant shift in NHP regulations was marked by the adoption of Bill C-47 in 2023, which incorporated NHPs under the scope of Vanessa's Law. This empowered Health Canada with enhanced authorities to better protect consumer safety, such as by recalling unsafe products from the market and mandating label changes where serious harm to health is identified. This goes into my third point, which is the pertinent need for greater oversight of NHPs. Between 2021 and 2022, Health Canada conducted inspections to assess the regulatory compliance of 36 NHP manufacturers and importers. All of the inspections identified compliance issues ranging in severity, with 15 of the 36 sites reporting issues serious enough to be considered non-compliance. Between 2021 and 2023 alone, there were also 100 voluntary recalls of licensed NHPs due to safety concerns, including contamination risks and the presence of harmful substances. These figures are not mere statistics. They represent potential harm to Canadian families and highlight the need to have stronger tools available to protect consumers from serious health and safety risks. With all that said, it is important to consider the crucial need for oversight of NHPs as we consider the implications of Bill C-368, which could significantly alter the government's ability to regulate the safety and efficacy of these important products. As the NHP market has grown significantly over the years in Canada and continues to grow, we continue to support access to a safe NHP marketplace for Canadians to maintain and improve their health. The extension of Vanessa's Law to NHPs underscores this commitment. As we navigate this conversation, let us prioritize the safety and trust of Canadians in their health product choices and ensure that the regulatory mechanisms in place are equipped to address the complexity of the NHP industry. I am thankful for the opportunity to voice these considerations on behalf of my constituents in Richmond Hill and Canadians everywhere who rely on NHPs for their health and well-being.
1056 words
  • Hear!
  • Rabble!
  • star_border
Context: House Hansard - 304 - Apr/29/24
Mr. Mark Gerretsen (Kingston and the Islands, Lib.)
  • Apr/29/24 8:14:10 p.m.
  • Watch
Madam Speaker, in the time I have, I am going to identify what I see as some myths that have unfortunately been created in the dialogue around this piece of legislation. One of those myths is that there is no data to support the need for the changes the government is making in the NHP program. In reality, in two years, Health Canada has received reports of over a thousand adverse reactions where NHPs had a suspected role, of which 772 were serious; they either required hospitalization or were life-threatening. Here is another fact to back up that myth not being true. A recent audit found that 88% of sample NHPs were advertised with false and misleading product information, and 56% had misleading label information. I look forward to continuing this later.
133 words
  • Hear!
  • Rabble!
  • star_border